[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642418":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":46,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":53,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Centre Medical ISM (Integrative Systemic Medicine)","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Lilian Lessedjina, M.D.","CONTACT","+337-82-83-40-83","dr.llessedjina@gmail.com",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Centre Médical ISM","RECRUITING","Boulogne-Billancourt","Île-de-France Region","92100","France","FR",{"type":24,"coordinates":25},"Point",[26,27],2.24128,48.83545,{"lat":27,"lon":26},[30],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100642418","photobiomodulation-for-chronic-pain-and-fatigue-in-hypermobile-ehlers-danlos-syndrome-pbm-sedh-01-100642418",false,"NCT07637084","Photobiomodulation for Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome (PBM-SEDh-01)","Effect of MLS® Class IV Laser Photobiomodulation on Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome: A Prospective Observational Pilot Study in Private Medical Practice","PBM-SEDh-01","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of hypermobile Ehlers-Danlos Syndrome (hEDS) according to 2017 International Consortium criteria\n* Chronic pain ≥ 3 months, average VAS score ≥ 4\u002F10 over the preceding week\n* Stable analgesic treatment for ≥ 4 weeks (if any)\n* Follow-up at Centre Médical ISM, Boulogne-Billancourt\n* Informed and non-opposition signed\n\nExclusion Criteria:\n\n* Suspicious or malignant skin lesion on areas to be treated\n* Non-modifiable photosensitizing treatment\n* Pregnancy or breastfeeding\n* Photosensitive epilepsy\n* Acute articular inflammatory flare at inclusion date\n* Analgesic treatment modification within 4 weeks prior to inclusion\n* Simultaneous participation in another research protocol","ALL","18 Years",{"count":44,"type":45},25,"ESTIMATED","10 Weeks","OBSERVATIONAL","This study evaluates the effect of photobiomodulation (PBM) therapy using a MLS® class IV laser on chronic pain and fatigue in patients with hypermobile Ehlers-Danlos Syndrome (hEDS). hEDS is a hereditary connective tissue disorder characterized by joint hypermobility, chronic pain, and debilitating fatigue, for which therapeutic options remain limited.\n\nParticipants will receive 10 PBM sessions over 5 weeks (2 sessions per week), using red and near-infrared light (808 nm continuous + 905 nm pulsed) applied to painful areas identified at baseline. Pain (Visual Analogue Scale), multidimensional fatigue (MFI-20), and quality of life (EQ-5D-5L) will be assessed at baseline (T0), end of treatment (week 5), and follow-up (week 10).\n\nThis is a pilot observational study - the first to document the effect of MLS® laser PBM in hEDS. No additional procedures beyond routine care are required.",[50,51,52],"Ehlers-Danlos Syndrome, Hypermobile","Chronic Pain","Fatigue Syndrome, Chronic",[54],"photobiomodulation; laser therapy; MLS laser; Ehlers-Danlos syndrome; chronic pain; fatigue; quality of life; observational study; pilot study","2026-06-11",{"date":57,"type":58},"2026-06-15","ACTUAL",{"date":60,"type":58},"2026-05-26",{"date":62,"type":45},"2027-09-30",{"name":5,"class":6},1]